New meningitis A vaccine is a “breakthrough” for 430 million people at risk

BMJ 2010; 341 doi: 10.1136/bmj.c3552 (Published 2 July 2010)
Cite this as: BMJ 2010;341:c3552

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Peter Moszynski
  1. 1London

    The approval by the World Health Organization of a low cost vaccine against meningitis has been hailed by the charity Médecins Sans Frontières as a move “full of promise” for the 430 million people at risk of the disease in the meningitis belt of sub-Saharan Africa.

    Cathy Hewison, the charity’s medical adviser, told the BMJ that the new vaccine, called MenAfriVac, could virtually eliminate the epidemic form of the disease but warned that the full rollout of this “much needed vaccine” depends on sufficient funds being mobilised. Médecins Sans Frontières has been leading the Campaign for Access to Essential Medicines.

    Dr Hewison said the existing vaccine “confers very short term protection, …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL